Read More

Cytokinetics To Host Investor Call On December 27 To Discuss The Topline Results From SEQUOIA-HCM, The Pivotal Phase 3 Clinical Trial Of Aficamten In Patients With Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from

CYTK